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Abstract
CD4+CD25+Foxp3+ regulatory T cells (Tregs) can inhibit cytotoxic responses. Though several studies have analyzed Treg
frequency in the peripheral blood mononuclear cells (PBMCs) of pancreatic ductal adenocarcinoma (PDA) patients using
flow cytometry (FCM), few studies have examined how intratumoral Tregs might contribute to immunosuppression in the
tumor microenvironment. Thus, the potential role of intratumoral Tregs in PDA patients remains to be elucidated. In this
study, we found that the percentages of Tregs, CD4+ T cells and CD8+ T cells were all increased significantly in tumor tissue
compared to control pancreatic tissue, as assessed via FCM, whereas the percentages of these cell types in PBMCs did not
differ between PDA patients and healthy volunteers. The percentages of CD8+ T cells in tumors were significantly lower than
in PDA patient PBMCs. In addition, the relative numbers of CD4+CD25+Foxp3+ Tregs and CD8+ T cells were negatively
correlated in the tissue of PDA patients, and the abundance of Tregs was significantly correlated with tumor differentiation.
Additionally, Foxp3+ T cells were observed more frequently in juxtatumoral stroma (immediately adjacent to the tumor
epithelial cells). Patients showing an increased prevalence of Foxp3+ T cells had a poorer prognosis, which was an
independent factor for patient survival. These results suggest that Tregs may promote PDA progression by inhibiting the
antitumor immunity of CD8+ T cells at local intratumoral sites. Moreover, a high proportion of Tregs in tumor tissues may
reflect suppressed antitumor immunity.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer deaths in
the USA and leads to an estimated 227,000 annual deaths
worldwide [1]. Pancreatic ductal adenocarcinomas (PDAs) evolve
through non-invasive precursor lesions, typically through pancre-
atic intraepithelial neoplasias. Early-stage pancreatic cancer is
usually clinically silent, and the disease only becomes apparent
after the tumor invades the surrounding tissues or metastasizes to
distant organs. Most people who present with symptoms attrib-
utable to pancreatic cancer exhibit advanced disease [2]. As early
PDA detection is difficult and there are few therapeutic strategies
available to treat advanced tumors, there is a pressing need to
develop novel therapies for advanced PDA.
Immunotherapy is an attractive strategy for cancer treatment
because the immune response specificity may circumvent many
side effects associated with the currently available clinical options
[3]. Effective CD8+ T cells that mediate cytotoxic killing may play
a crucial role in the antitumor immune reaction by releasing
granules such as perforin and granzymes [4]. Recently, several
studies have shown that tumor-infiltrating CD8+ T cells prolong
survival in patients with cervical carcinoma and ovarian Cancer
[5,6]. Moreover, intratumoral CD8+ T cells abundance was
positively correlated with a good survival in PDA patients [7].
Therefore, tumor-infiltrating CD8+ T cells are believed to be a
favorable prognostic indicator in a variety of tumors. However,
cancer cells protect themselves from co-stimulatory molecules on
the cell surface and via the secretion of cytokines, such as IL-10
and TGF-b, to alter the tumor microenvironment and diminish
the antitumor response efficacy [8]. IL-10 and TGF-b are the most
important cytokines for the differentiation of naive T cells into
Tregs [9]. In contrast, Tregs have previously been reported to
reduce the effects of immune T cells, such as CD8+ T cells, or to
suppress T cell functions, leading tumor cells to escape immune
surveillance [10,11].
The immune system constitutes an important part of the tumor
microenvironment, and it is thought to be critical for cancer
development and progression. Many studies have suggested that
Tregs are major players in tumor immune suppression [12] and
that they represent the main obstacle to successful tumor
immunotherapy [13,14]. Tregs accumulate in tumors and in the
peripheral blood of patients with cancer [15–17]. Increasingly,
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studies have confirmed that Tregs are recruited to tumor sites,
where they suppress antitumor cytotoxic responses [18–20]. It has
been shown that the numbers of CD4+CD25+Foxp3+ Tregs are
increased in the peripheral blood mononuclear cells (PBMCs) and
draining lymph nodes of human colon cancer patients, and these
Tregs are capable of suppressing antigen-specific CD4+ T cells
[21]. The surgical removal of colon cancer reduces the Treg
population and restores the antigen-specific T cell activity of CD4+
T cells [22]. Immunoregulatory mechanisms present in the tumor
microenvironment, including in the liver [23], breasts [24,25] and
ovaries [26], may contribute to tumor outgrowth. Immunohisto-
chemical (IHC) studies have revealed the presence of Foxp3+ T
cells in PDA tissue and shown their correlation with a poor clinical
prognosis [27,28]. Several studies have analyzed the frequency of
Tregs using FCM in the PBMCs of PDA patients [29,30].
However, the proportion of T cell subtypes in PDA tissue where
the T cells would function on tumor cells, have not been
elucidated by FCM. In addition, animal models show that Tregs
actively infiltrate the stromal compartment of pancreatic intraep-
ithelial neoplasias and PDAs, even in the earliest tumor
development stages, and display local immunosuppression [31].
Therefore, it is necessary to assess the Treg distribution details in
PDA tissue to investigate the mechanisms underlying the potential
Treg effects in PDA.
This study was therefore designed to examine the role of tumor-
infiltrating Tregs that can potentially affect the tumor-specific T-
cell response in patients with PDA. The proportions of CD4+/
CD8+ T cells and Tregs in tumor-infiltrating lymphocytes (TILs)
and in the PBMCs of PDA patients were analyzed using FCM. To
analyze the correlation between Treg abundance and the
abundance of CD8+ T cells or CD4+ T cells in the PDA
microenvironment, we also investigated the relationship between
the proportion of tumor-infiltrating CD8+ T cells or Tregs and
clinicopathologic characteristics. After verifying the expression of
CD4+ and Foxp3+ T cells in PDA tissue via IHC, the relationship
of CD4 and Foxp3 expression with PDA patient survival was
analyzed. These results suggest that Tregs may inhibit the
antitumor immunity of CD8+ T cells in PDA and be correlated
with poor PDA differentiation.
Materials and Methods
Ethics Statement
This study was approved by the ethical committee of Southwest
Hospital. All patients provided written informed consent.
General information
In total, 228 patients with PDA and 15 healthy controls treated
at Southwest Hospital between January 2007 and January 2012
were enrolled in this study. Of these patients, 143 were male, and
85 were female. Their average age was 57.13612.16 years. Forty-
five patients were analyzed using FCM, and 183 patients were
analyzed using only IHC. The patients’ demographics and tumor
characteristics, including the tumor stage, lymph node metastasis,
tumor size and degree of differentiation, are shown in Table 1.
None of the patients received radiotherapy, chemotherapy or
other medical interventions. The 15 controls included 10 male and
5 female individuals with an average age of 55.8669.10 years. The
patients and controls were matched for both sex and age.
Blood and tissue samples
During the study, 45 additional patients and 15 healthy
volunteers were enrolled. PBMCs were isolated via Lymphoprep
(Roche, Basel, Switzerland) density gradient centrifugation.
Tumor specimens and normal pancreatic tissue specimens were
obtained from the PDAs of patients or at the distal ends of the
surgical margin; the non-tumor portions were verified to be free of
cancer involvement through microscopic examination. Fresh
tumor samples were collected during surgery and chopped into
small pieces using a razor blade in RPMI 1640 medium. These
tissues were mixed with 1 mg/ml collagenase-IV (Sigma-Aldrich,
St. Louis, MO) and 10 mg/ml DNase I (Roche, Basel, Switzer-
land) in Hank’s buffered salt solution for 30 minutes at 37uC and
then mechanically dissociated with a MACS Dissociator (Miltenyi
Biotec, Bergisch Gladbach, Germany), followed by filtration
through a 70-mm nylon mesh. Single-cell suspensions were
separated with Lymphoprep (Roche, Basel, Switzerland). The
tumor tissue samples from 183 patients were fixed in 4%
paraformaldehyde and embedded in paraffin for histopathological
analysis.
Table 1. Patient demographic and tumor characteristics.
Clinicopathologic characteristics Results
Total cases 228
Age(years)
Mean (6SD) 57.13612.16
Median (range) 66 (33–78)
Gender
Male 147
Female 81
Tumor size (mm)
Mean (6SD) 42.7615.3
Median (range) 37 (18–109)
Pathologic tumor status
pT1 41
pT2 80
pT3 92
pT4 15
Regional lymph node status
N0 178
N1 50
Distant metastasis status
M0 213
M1 15
Stage
I+II 187
III+IV 41
Tumor differentiation
Well 48
Moderate 106
Poor 51
Other histologic type 23
Perineural invasion(absent/present) 171/57
Vascular invasion(absent/present) 195/33
Note: Classified according to International Union Against Cancer tumor-node-
metastasis classification.
doi:10.1371/journal.pone.0091551.t001
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FCM
Cells from tissue samples and PBMC suspensions were
incubated in 1 ml of PBS with 1 ml per sample of LIVE/DEAD
Fixable Red Dead Stain (Invitrogen) for 30 minutes on ice in the
dark. The cells were washed, re-suspended and stained with anti-
human CD3 APC-eFluor780 (47-0036, eBioscience), CD4-FITC
(11-0048-41, eBioscience), CD8 PerCP-Cy5.5 (45-0088,
eBioscience) and CD25-PE antibodies (12-0259-41, eBioscience).
After 30 minutes on ice, the samples were washed and fixed in
PBS containing 1% paraformaldehyde (PFA; Sigma-Aldrich). The
cells were washed and resuspended with 1 ml of permeabilization
buffer (00-5523-00 Foxp3 Staining Buffer Set eBioscience) for one
hour and then washed and incubated for 30 minutes in
permeabilization buffer containing APC-conjugated antibodies
against Foxp3 (12-4776-41, eBioscience). Isotype controls were
used to enable accurate compensation and to confirm antibody
specificity. The stained cells were analyzed via FCM using a FACS
Calibur flow cytometer (BD Bioscience PharMingen, San Jose,
CA, USA) equipped with CellQuest software (BD Bioscience
PharMingen, San Jose, CA, USA).
Immunohistochemistry
Consecutive 5-mm sections were cut from the paraffin-embed-
ded samples. For antigen retrieval, the de-paraffinized sections
were boiled for 2.5 minutes in citrate buffer, pH 6.0. Endogenous
peroxidase activity was blocked through incubation with a 3%
hydrogen peroxide solution for 20 minutes at room temperature.
Primary antibody dilutions were prepared as follows: mouse anti-
human-Foxp3 (monoclonal, 1:100 dilution, Biosynthesis Biotech,
Abcam), rabbit anti-human-CD8 (monoclonal, 1:100 dilution,
RMA-0514, Maixin, China) and rabbit anti-human-CD4 (mono-
clonal, 1:100 dilution, Biosynthesis Biotech, Maixin, China) at 4uC
overnight, followed by incubation with a horseradish peroxidase-
labeled polymer conjugated to the secondary goat anti-mouse/
rabbit antibody (KIT-9710; Maixin, China) at 37uC for 30 min-
utes. Finally, the signal was developed with 3,39-diaminobenzidine
(DAB-2031; Maixin, China), and all slides were counterstained
with hematoxylin. Negative controls were treated with PBS instead
of the primary antibodies.
Scoring system for immunohistochemistry analysis
The FoxP3 and CD4 distributions were observed under an
optical microscope (BX51; Olympus, Tokyo, Japan) by indepen-
dent pathologists who were blinded to the clinical outcome, and
positive staining was quantitatively evaluated using Image-Pro Plus
5.1 software (Media Cybernetics, Inc., Silver Spring, Md., USA) in
at least five different high-power fields (206 objective and 106
eyepiece). The number of Foxp3+, CD4+ lymphocytes was
calculated for each field, and the averages were compared.
Data processing
All data are expressed as the median values and ranges.
Comparisons between the two groups were assessed using
Student’s t test. Correlations between the parameters were
assessed through Pearson correlation analysis and linear regression
analysis. The X2 test or Fisher’s exact test was used to compare
categorical variables when associating the Treg and CD8+ T cell
prevalences with various clinicopathologic variables. Survival rates
were calculated using the Kaplan-Meier method. Survival analysis
began on the day of surgical resection and ended on the day of
death or at the end of observations. Differences between survival
curves were analyzed using log-rank tests. Multivariate analyses
were performed using the Cox proportional hazards regression
model. Statistical analyses were conducted using Graph Pad Prism
5.0 software. P values less than 0.05 were considered statistically
significant (* P,0.05; ** P,0.01; *** P,0.001).
Results
Up-regulation of CD4+T, CD8+T and Treg cells in PDA
tissue
The proportions of T cells in PBMCs and in pancreatic tissue or
PDA tissue collected from 15 healthy controls and 45 PDA
patients (28 males and 17 females with a mean age of 57 years)
were analyzed via FCM. The results showed that the percentages
of CD8+ T cells (PDA-PBMC vs. C-PBMC: 34.2860.8431% vs.
30.9460.8405%), CD4+ T cells (PDA-PBMC vs. C-PBMC:
54.5160.9725% vs. 57.1760.6233%) and Tregs (PDA-PBMC vs.
C-PBMC: 5.75560.145% vs. 5.77260.2105%) in PBMCs were
not markedly different between PDA patients and healthy
volunteers (Figure 1D). We also observed that the proportions
of CD4+ T cells (PDA-TIL vs. C-PT: 59.4760.5974% vs.
12.661.343%) and Tregs (PDA-TIL vs. C-PT: 17.860.7075%
vs. 0.0160.005%) in TILs were markedly increased compared to
C-PTLs (both P,0.001) (Figure 1B, 1C and 1D). However, the
proportion of CD8+ T cells in the TILs of PDAs was significantly
higher than that in control pancreatic tissue lymphocytes (C-PTLs)
(29.4860.5353% vs. 4.28260.2738%, P,0.001) (Figure 1B and
1D). Taken together, these data demonstrate an enrichment of
CD8+ T cells, CD4+ T cells and Tregs in PDA tissue relative to
healthy pancreatic tissue, suggesting that T cell immunity and
Tregs may be playing an important role in the development and
progression of PDA.
When the relative frequency of T subtypes was compared
between the PBMCs and TILs of PDA patients, we found that the
percentages of CD4+ T cells and Tregs in TILs were increased
compared to the percentages in PDA PBMCs (both P,0.001)
(Figure. 1B, 1C and 1D). However, the percentage of CD8+ T
cells was down-regulated in PDA TILs (PDA TILs vs. PDA
PBMCs: 29.4860.5353% vs. 34.2860.8431%, P,0.001)
(Figure 1B and 1D). In contrast, the proportions of CD8+T
cells, CD4+T cells and Tregs in the pancreatic tissues of healthy
controls were much lower than in PBMCs (Figure 1B, 1C and
1D).
Association of tumor-infiltrating Tregs with
clinicopathologic characteristics
We investigated the Treg role in the PDA microenvironment by
correlating the proportions of Tregs and CD4+ T cells or CD8+ T
cells in the tumor tissues of PDA patients. We found that the
relative intratumoral Treg abundance was positively correlated
with the relative intratumoral CD4+ T cell abundance
(R=0.2254, P=0.001) (Figure 2A) but negatively correlated
with the relative intratumoral CD8+ T cell abundance
(R=0.2166, P=0.0013) (Figure 2B). These data suggest that
Tregs may promote PDA progression by inhibiting the antitumor
immunity of CD8+ T cells at local intratumoral sites.
To explore the possible roles of tumor-infiltrating Tregs and
CD8+ T cells in the development of PDA, we analyzed the
correlation between the proportion of tumor-infiltrating Tregs or
CD8+ T cells and the clinicopathologic PDA characteristics. PDA
patients were divided into two groups based on the median value
obtained for either tumor-infiltrating Tregs (17.37% in CD4+ T
cells) or tumor-infiltrating CD8+ T cells (28.69% in CD3+ T cells)
(Table 2). The results indicated that the proportion of
intratumoral CD8+ T cells was not correlated with any clinico-
pathologic characteristics. The number of tumor-infiltrating Tregs
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showed a significant positive correlation with tumor differentiation
(P,0.001) but was not correlated with tumor pathologic metastasis
or tumor micro-vascular invasion. Therefore, increased numbers
of tumor-infiltrating Tregs may be correlated with the microen-
vironment and PDA differentiation.
Foxp3+ cells were observed more frequently in tumor
tissue
The above results indicated that the percentages of
CD4+CD25+FoxP3+ Tregs were increased, as assessed via FCM.
To confirm these findings and examine the correlation between
tumor-infiltrating Foxp3+ T cells and the clinicopathologic PDA
Figure 1. Flow cytometric analysis of the T cell subtype proportions. The proportions of CD4+ T cells, CD8+ T cells and Tregs in PBMCs and in
pancreatic tissue lymphocytes or tumor-infiltrating lymphocytes from healthy control and PDA patients were analyzed via FCM. (A) Lymphocyte dot
plots. The gate for lymphocytes is indicated. (B) CD4+ and CD8+ T cells were defined based on CD4+CD82 and CD8+CD42 gating of CD3+ T cells. (C)
Dot plots of Foxp3+CD25+ (Treg) cells based on the gating of CD4+ T cells. (D) Statistical analyses of the CD8+ T cell, CD4+ T cell and Treg percentages
in the indicated groups. C-PBMCs, control peripheral blood mononuclear cells; PDA-PBMCs, PBMCs of PDA; C-PTL, control pancreatic tissue
lymphocytes; PDA-TIL, tumor-infiltrating lymphocytes of PDA. Comparisons between the two groups were assessed using Student’s t test. NS, not
significant; *** P,0.001.
doi:10.1371/journal.pone.0091551.g001
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Figure 2. Correlation between tumor-infiltrating Tregs and CD4+ T cells or CD8+ T cells in PDA tissue. The correlation of the tumor-
infiltrating Treg frequency with that of tumor-infiltrating CD4+ T cells or tumor-infiltrating CD8+ T cells was analyzed. Correlations between the
parameters were assessed through Pearson correlation analysis.
doi:10.1371/journal.pone.0091551.g002
Table 2. Correlations between tumor-infiltrating Tregs or CD8+ T cells and the clinicopathologic characteristics of 45 patients with
PDA.
Characteristics Intratumor CD8
+ T cells MV=28.69% Intratumor Tregs MV=17.37%
Low(n=23) High(n =22) P Low(n=23) High(n=22) P
Sex
Male 15(65.2) 13(59.1) 16(69.6) 12(54.5)
Female 8(34.8) 9(40.9) 1.001 7(30.4) 10(45.4) 0.3651
Mean age 6 SD, years 54.67610.42 57.17610.54 0.4292 56.04610.91 55.95610.18 0.9782
Pathologic tumor status
pT1 5(21.7) 3(13.6) 6(26.1) 2(9.1)
pT2 7(30.4) 5(22.7) 7(30.4) 5(22.7)
pT3 9(39.1) 12(54.5) 8(34.8) 13(59.1)
pT4 2(8.7) 2(9.1) 0.5581 2(8.7) 2(9.1) 0.3201
Pathologic metastasis status
M0 20(87.0) 20(90.9) 21(91.3) 19(86.4)
M1 3(13.0) 2(9.1) 0.8721 2(8.7) 3(13.6) 0.5981
Pathologic node status
N0 19(82.6) 18(81.8) 20(87.0) 17(77.3)
N1 4(17.3) 4(18.1) 1.001 3(13.0) 5(22.7) 0.2431
Stage
I+II 17(73.9) 17(77.3) 17(73.9) 17(77.3)
III+IV 6(26.1) 5(22.7) 0.7931 6(26.1) 5(22.7) 0.7931
Tumor Grade
Well 1(4.3) 8(36.4) 9(39.1) 0(0)
Moderate 13(56.5) 10(45.5) 13(56.5) 10(45.5)
Poor 9(39.1) 4(18.2) 0.0611 1(4.3) 12(54.5) ,0.0011
Vascular invasion
Present 6(26.1) 3(13.6) 4(17.4) 5(22.7)
Absent 17(73.9) 19(86.4) 0.4591 19(82.6) 17(77.3) 0.7221
Perineural invasion
Present 8(34.8) 6(27.2) 7(30.4) 7(31.8)
Absent 15(65.2) 16(72.7) 0.7491 16(69.6) 15(68.2) 1.001
1x2 test or Fisher’s exact test;
2Student’s t test. MV=median value.
Classified according to International Union Against Cancer tumor-node-metastasis classification.
doi:10.1371/journal.pone.0091551.t002
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characteristics, we examined the Foxp3+ T cell abundance in
PDA tissues from 160 patients and five control specimens
(Figure 3). Though obvious CD4, CD8 and Foxp3 expression
were not observed in normal pancreatic tissue, Foxp3 was strongly
expressed in the tumor stroma, with more Foxp3+ cells have been
observed in the PDA juxtatumoral stroma than in the PDA
panstroma (P=0.0043, R= 0.02217) (Figure 3). We next
analyzed the distribution of CD8+ cells within the stromal of
PDA and found that the CD8+ cells were significantly reduced in
the juxtatumoral stroma compared with the panstromal areas
(P,0.0001, R= 0.4802) (Figure 3). Interestingly, although many
CD4+ cells had infiltrated the PDA juxtatumoral stroma and the
PDA panstroma, the frequency of CD4+ cells did not significantly
differ between the local sites (P=0.1264, R= 0.0064) (Figure 3).
To determine if the proportion of intratumoral Foxp3+ cells
correlated with any clinicopathological characteristic, the 160
patients were split into two groups based on the median
percentage of intratumoral Foxp3+ cells. Of the examined
characteristics, only the intratumoral abundance of Foxp3+ T
cells was correlated with tumor differentiation, the pathologic
tumor status, tumor stage and lymphatic invasion (Table S1).
Prognostic significance of Foxp3+, CD8+ and CD4+ cells in
the PDA microenvironment
Kaplan-Meier univariate survival analysis showed that the
overall survival rate was significantly reduced in patients showing
an increased intratumoral Foxp3+ cell density compared to those
with a lower Foxp3+ cell density, as determined through IHC
assays (P,0.0001, Figure 4A and Table 3). Thus, patients with a
high number of tumor-infiltrating Foxp3+ cells display an
unfavorable prognosis. We also found a higher number of
tumor-infiltrating CD8+ cells were associated with an improved
survival (P=0.0016, Figure 4D and Table 3). In contrast, the
overall survival rates of patients with low versus high numbers of
CD4+ cells did not significantly differ (P=0.8082, Table 3). A
multivariate Cox proportional hazards model analysis was
performed, and variables that were associated with survival based
on univariate analysis were adopted as covariates (Table 3). The
multivariate analysis indicated that the intratumoral density of
Foxp3+ cells (hazard ratio (HR)= 0.3162, P,0.0001), histologic
grade (HR=0.3189, P=0.0018, Figure 4B) and TNM stage
(HR=0.2185, P= 0.0162, Figure 4C) were independent prog-
nostic factors for the PDA patient overall survival. These results
suggest that increased intratumoral Foxp3+ cell numbers are
associated with PDA progression and may serve as an independent
predictor of poor survival in PDA patients.
Discussion
TILs are a key component of the host immune response to
cancer in the tumor microenvironment. Tregs potentially affect
the TILs found in several types of human tumors, thus impairing
cell-mediated immunity and promoting disease progression [32–
34]. Increased percentages of CD4+CD25+ Tregs in PBMCs have
been reported in patients with several types of human cancer
[35,36], including pancreatic cancer [30]. However, using FCM,
we did not detect a significant difference in the relative abundance
of CD4+CD25+Foxp3+ Tregs in the blood of PDA patients versus
healthy controls. We speculate that this discrepancy in our results
have been attributable to the definition of Treg cells. It has known
that the activated T cells also express CD25, thus CD4 and CD25
Figure 3. IHC analysis of paraffin-embedded tumor sections from patients with PDA or control pancreatic tissue. Magnification: 2006.
Comparisons of FoxP3+ cell, CD8+ cell and CD4+ cell infiltrates between the juxtatumoral stroma and the panstroma. IHC analyzed the expression of
Foxp3, CD4 and CD8 and statistical analysis the frequencies in juxtatumoral stroma and in panstroma. Comparisons between the two groups were
assessed using Student’s t test. NS, not significant; ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0091551.g003
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double positive T cells probably do not represent the authentic
Treg cells that should express the signature transcription factor
Foxp3. Therefore, the CD4+CD25+Foxp3+ Treg frequency in this
study should reflect the real Treg level in PDA patients, which is
not significantly different from that in healthy control. These
results also suggest the definition of Treg cell should be used with
caution, which otherwise might cause the contradictory results as
described above.
Though there is no apparent difference of Treg cells in PDA
patients from that in controls, we found that the frequency of
CD4+CD25+Foxp3+ Tregs was significantly higher in PDA tissues
compared to the healthy pancreatic tissues. Moreover, using IHC,
Figure 4. Survival curves for univariate analyses. (A) The survival rates of PDA patients with a high or low proportion of intratumoral Foxp3+
cells were estimated by the Kaplan-Meier method. The log-rank test was applied to compare the two groups. (B) Survival rates for patients with
different tumor histological grades were estimated by the Kaplan-Meier method. (C) Survival rates for patients with the indicated TNM stages were
estimated by the Kaplan-Meier method. (D) Survival rates for patients with a high or low proportion of intratumoral CD8+ cells were estimated by the
Kaplan-Meier method.
doi:10.1371/journal.pone.0091551.g004
Table 3. Univariate and multivariate analyses of the association of clinicopathologic characteristics with overall survival in 160
patients with PDA.
Univariate analysis Multivariate analysis
Variables Categories MST (95%CI) Overall survival Overall survival
HR 95% CI P HR 95% CI P
Age #58 530(374.4–685.6) 0.8218 0.5765–1.2653 0.2152 1.327 0.7576–1.9519 0.3574
.58 years 428(293.3–562.7)
Sex Male 525(388.2–611.8) 0.8378 0.5854–1.2416 0.3316 0.8546 0.5916–1.2753 0.4361
Female 400(268.2–531.8)
Histologic grade Well 587(475.0–699.0) 0.3427 0.2416–0.4741 ,0.0001 0.3453 0.2636–1.5325 0.0025*
Moderate+Poor 280(204.7–355.3)
Tumor status T1+pT2+pT3 472(459.9–635.7) 0.3931 0.1831–1.0359 0.0413 0.3135 0.1364–0.5935 0.0743
pT4 305(200.9–443.1)
Node status pN0 471(458.0–628.0) 0.6925 0.5855–1.035 0.0910 0.7493 0.5143–0.9463 0.3637
pN1 374(327.0–518.7)
Metastasis pM0 448(485.3–600.6) 0.3642 0.1546–0.8613 0.0215 0.3169 0.1424–0.7328 0.2426
status pM1 334(186.5–451.9)
TNM stage I–II 472(374.4–486.8) 0.4143 0.3142–0.6732 0.0013 0.3785 0.1693–0.7472 0.0393*
III–IV 331(214.4–391.1)
Vascular Present 472(370.8–481.4) 0.3713 0.2536–0.6834 0.0063 0.1843 0.1492–0.4951 0.0837
invasion absent 325(209.8–390.0)
Intratumor: low/high1
Foxp3+ Cells Low 637(504.4–667.6) 0.3414 0.2511–0.4963 ,0.0001 0.3351 0.2215–0.5457 0.0001*
high 289(227.1–325.9)
CD4+ T cells Low 342(279.3–399.3) 0.9647 0.6735–1.384 0.8235 0.8336 0.6146–1.2483 0.7257
high 531(398.4–563.5)
CD8+ T cells Low 176(127.5–225.8) 0.5643 0.3957–0.8046 0.0016 0.7582 0.5357–1.063 0.5369
high 393(296.8–424.6)
1Two groups were divided by the median value. Excluded the special histologic type. (23 cases).
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; MST, median survival time.
*Significant.
doi:10.1371/journal.pone.0091551.t003
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we also detected a high density of intratumoral FoxP3+ Tregs in
PDAs, similar to results observed in other malignancies, including
breast, ovarian, gastric and esophageal cancers [37–39]. This
finding indicates that Tregs are significantly enriched in PDA
tissues relative to the healthy pancreatic tissue, suggesting that
Tregs are recruited to and remain in the PDA microenvironment
to function. Due to the technical limitation, the IHC results could
not reflect the real frequency of Treg cells in PDA tissues, which
needs multiple color labeling technique. In this study, we firstly
accurately defined the proportion of T cell subtypes including
Treg cells in PDA tissue by FCM. The results further confirmed
that the Treg frequency in the pancreatic tissues was much higher
than that in healthy control.
We also found that the CD8+ T cell percentage was up-
regulated in the PBMCs of PDA patients compared to PDA tissues
and control PBMCs. Additionally, the relative intratumoral Treg
and intratumoral CD8+ T cell abundances were negatively
correlated in tumor tissue. These results are consistent with those
found in other types of tumor tissues [40]. These findings indicate
that a high proportion of intratumoral Tregs exists in PDA tissues,
while CD8+ T cell recruitment is blocked. As such, by FCM, we
evaluated correlations of the frequency of CD8+ T cells and
CD4+CD25+Foxp3+ Tregs in PDA tissue with clinicopathologic
characteristics. The findings suggest that the increased number of
intratumoral Tregs was just only correlated with the tumor grade.
However, by using IHC strategy, other researchers reported that
the increased number of intratumoral Tregs were correlated with
tumor status, pathologic metastasis status [27] and venous invasion
[28]. These findings were consistent with our results that there
were good correlation between tumor-infiltrating Foxp3+ cells and
the clinicopathologic characteristics of 160 patients with PDA by
using immunohistochemical staining (Table S1). To our knowl-
edge, the activated CD4+T cells that transiently express Foxp3
may differentiate into memory T effector cells [41]. Therefore,
using Foxp3 as the sole marker of Tregs may lead to discordant
conclusions, and multistaining FCM assays might provide more
accurate Treg frequency in tumor tissues than IHC-based
methodology. Taken together, our observations of high propor-
tions of CD4+CD25+FoxP3+ Tregs in tumors and CD8+ T cell
recruitment blockage strongly support the possibility that these
Tregs may inhibit local antitumor immunity at the tumor site.
Tregs isolated from the tumor region can suppress autologous
CD8+ T cell proliferation in vitro [42]. It is suggested that the local
Treg abundance was achieved by suppressing the proliferation or
migration of CD8+ T cells in PDA tissue. Results also suggested
that, as the Treg cell population is the major suppressor in tumor
immunity, targeting this sub-population rather than whole T cell
population may represent a promising method for tumor
immunotherapy.
A high intratumoral Treg density creates a generalized
immunosuppressive microenvironment and contributes to tumor
cell escape from immune surveillance [43]. The present study
revealed high Foxp3+ cell numbers and a low-density CD8+ cells
in the juxtatumoral stroma. However, the tumor stroma and
normal pancreatic tissues did not show a high Foxp3+ cell
prevalence. Our findings suggest that a higher number of tumor-
infiltrating CD8+ cells were associated with a good survival but the
PDA tumor microenvironment can recruit large numbers of
functional Tregs, which can locally suppress the tumor-specific T-
cell response. We conclude that the large Treg presence in the
juxtatumoral stroma leads the tumor cells to evade the immune
response, and the lack of low Treg numbers in the panstroma
results in greater inflammation that promotes tumor invasion.
Other studies have shown that Treg depletion results in enhanced
antitumor responses and inhibits tumor growth [44,45]. Further-
more, Treg-depleted CD4+ T cell transfer markedly augmented
CD8+ T cell antitumor immune responses [11]. Cyclophospha-
mide administration, which preferentially removes CD4+CD25+
Tregs but not effector T cells, activated a latent pool of high-
avidity tumor antigen-specific CD8+ T cells [46,47]. These study
results are consistent with our findings and are relevant for guiding
immunotherapy targeting PDA.
In conclusion, our data demonstrate that the frequency of
CD4+CD25+Foxp3+ Tregs is significantly increased in PDA tissue
and that these cells inhibit tumor-associated antigen-specific CD8+
T cells. Furthermore, the increased tumor-infiltrating Treg
abundance is positively correlated with PDA tumor cell differen-
tiation and indicates a poor prognosis. The majority of Foxp3+
cells were found local to poorly differentiated PDA tumor cells.
This observation is supported by our finding that the poorly
differentiated PDA microenvironment recruits a high number of
intratumoral Tregs, leading to a tumor cell immune evasion
response and low survival rate among PDA patients. The
panstroma exhibits a relatively low Treg abundance, which
induces an inflammatory response in the stroma of the PDA
microenvironment. Future studies should further explore the
attenuation of Tregs around poorly differentiated PDA tumor
cells; it is possible that the cytotoxic T cells and high density of
Tregs observed in the juxtatumoral stroma that migrate to the
panstroma can lead to diminished PDA tumor cells invasion.
Supporting Information
Table S1 Verification of the correlation between tumor-
infiltrating Foxp3+ T cells and the clinicopathologic
characteristics of 160 patients with PDA via immuno-
histochemical staining.
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